Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir vs Lopinavir/Ritonavir as Second-line Therapy in HIV-1 (China)
CTR20150350Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by GSK. Started Jul 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20150350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150350.